Celtic Therapeutics Earmarks $50M For ADC Therapeutics
This article was originally published in The Pink Sheet Daily
Private equity firm Celtic Therapeutics is promising a $50 million investment in ADC Therapeutics, a new company that will work closely with Celtic’s other investment Spirogen on antibody-drug conjugates.
You may also be interested in...
Financings Of The Fortnight Sees New Biotech Funding All Over The Globe, And Without Much VC Participation
Plus news on recent financial activity by Merrimack, Promethera, ADC Therapeutics and Enterome Bioscience.
The company touted its proprietary pipeline at an investor day as it turns its focus away from partnerships and toward its internal research.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.